Mouse Genome Informatics
cx
    Tg(KRT5-rtTA)1Glk/0
Tg(tetO/CMV-Tslp)#Sfz/0

involves: C3H * C57BL/6 * FVB/N
Key:
phenotype observed in females WTSI Wellcome Trust Sanger Institute
phenotype observed in males EuPh Europhenome
N normal phenotype
       
integument
• by 5 weeks of doxycycline (dox) treatment, lesional skin shows characteristic changes of eczematous inflammation including spongiosis
• dox treated mutants exhibit dermal infiltrates containing lymphocytes, macrophages, mast cells, and eosinophils
• mutants treated with doxycycline (dox) to induce expression of Tslp develop skin disease beginning at about 2-3 weeks of dox treatment
• however, inflammation is not seen in the small intestine or colon
• by 5 weeks of dox treatment, lesional skin shows characteristic changes of eczematous inflammation including hyperkeratosis
• by 5 weeks of dox treatment, lesional skin shows characteristic changes of eczematous inflammation including acanthosis
• majority of dox treated mice exhibit a mild xerosis
• seen in dox treated mutants
• dox treated mutants exhibit skin lesions consisting of mild erythema at 2 weeks of dox treatment with progression to eczematous-like changes, including erythema, crusting, and erosions, by 3-4 weeks of dox treatment
• skin lesions are most common on the snout, postauricular region, nape of the neck and upper back
• less commonly, lesions are seen on the anterior neck and hind legs

immune system
• dox treated mutants exhibit an increase in the frequency of and absolute numbers of IL-4 producing Th2 CD4+ T cells in both the spleens and lymph nodes
• dox treated mutants exhibit splenomegaly
• in dox treated mutants
• in dox treated mutants
• in dox treated mutants
• dox treated mutants exhibit an increase in Th2 cytokines in effected skin
• dox treated mutants exhibit a 14-fold increase in IL-4 producing cells in the skin-draining lymph nodes and an 18-fold increase in the intestinal mesenteric lymph nodes
• dox treated mutants exhibit lymphadenopathy
• a few dox treated mice exhibit conjunctivitis
• mutants treated with doxycycline (dox) to induce expression of Tslp develop skin disease beginning at about 2-3 weeks of dox treatment
• dox treated mutants exhibit dermal infiltrates containing lymphocytes, macrophages, mast cells, and eosinophils
• however, inflammation is not seen in the small intestine or colon

hematopoietic system
• dox treated mutants exhibit an increase in the frequency of and absolute numbers of IL-4 producing Th2 CD4+ T cells in both the spleens and lymph nodes
• dox treated mutants exhibit splenomegaly
• in dox treated mutants
• in dox treated mutants
• in dox treated mutants

homeostasis/metabolism
• by 5 weeks of doxycycline (dox) treatment, lesional skin shows characteristic changes of eczematous inflammation including spongiosis
• dox treated mutants exhibit an increase in Th2 cytokines in effected skin

vision/eye
• a few dox treated mice exhibit conjunctivitis

Mouse Models of Human Disease
OMIM IDRef(s)
Dermatitis, Atopic 603165 J:100506